4.6 Article

Changes in Blood Pressure and Arterial Hemodynamics following Living Kidney Donation

期刊

出版社

AMER SOC NEPHROLOGY
DOI: 10.2215/CJN.15651219

关键词

blood pressure; arterial stiffness; hypertension; living kidney donors; chronic kidney disease; pulse wave velocity; arteries; hemodynamics

资金

  1. British Heart Foundation [PG/12/35/29403]
  2. AstraZeneca
  3. Wellcome
  4. British Heart Foundation clinical training fellowship [FS/16/73/32314]
  5. Wellcome Trust intermediate clinical fellowship [101143/Z/13/Z]

向作者/读者索取更多资源

Background and objectives: The Effect of a Reduction in GFR after Nephrectomy on Arterial Stiffness and Central Hemodynamics (EARNEST) study was a multicenter, prospective, controlled study designed to investigate the associations of an isolated reduction in kidney function on BP and arterial hemodynamics. Design, setting, participants, & measurements: Prospective living kidney donors and healthy controls who fulfilled criteria for donation were recruited from centers with expertise in vascular research. Participants underwent office and ambulatory BP measurement, assessment of arterial stiffness, and biochemical tests at baseline and 12 months. Results: A total of 469 participants were recruited, and 306 (168 donors and 138 controls) were followed up at 12 months. In the donor group, mean eGFR was 27 ml/min per 1.73 m(2) lower than baseline at 12 months. Compared with baseline, at 12 months the mean within-group difference in ambulatory day systolic BP in donors was 0.1 mm Hg (95% confidence interval, -1.7 to 1.9) and 0.6 mm Hg (95% confidence interval, -0.7 to 2.0) in controls. The between-group difference was -0.5 mm Hg (95% confidence interval, -2.8 to 1.7; P=0.62). The mean within-group difference in pulse wave velocity in donors was 0.3 m/s (95% confidence interval, 0.1 to 0.4) and 0.2 m/s (95% confidence interval, -0.0 to 0.4) in controls. The between-group difference was 0.1 m/s (95% confidence interval, -0.2 to 0.3; P=0.49). Conclusions: Changes in ambulatory peripheral BP and pulse wave velocity in kidney donors at 12 months after nephrectomy were small and not different from controls.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Peripheral Vascular Disease

Hypertension and cardiomyopathy associated with chronic kidney disease: epidemiology, pathogenesis and treatment considerations

Jonathan P. Law, Luke Pickup, Davor Pavlovic, Jonathan N. Townend, Charles J. Ferro

Summary: Chronic kidney disease (CKD) is a complex condition that affects 10-15% of the global population. There is an inverse relationship between kidney function and cardiovascular events and mortality, independent of age, sex, and other risk factors. The development of CKD-associated cardiomyopathy, characterized by left ventricular changes and fibrosis, is significantly influenced by hypertension. Even in mild to moderate renal impairment, structural and functional changes consistent with CKD-associated cardiomyopathy can be observed.

JOURNAL OF HUMAN HYPERTENSION (2023)

Article Transplantation

Self-reported health change in haemodialysis recipients modulates the effect of frailty upon mortality and hospital admissions: outcomes from a large prospective UK cohort

Benjamin M. Anderson, Muhammad Qasim, Gonzalo Correa, Felicity Evison, Suzy Gallier, Charles J. Ferro, Thomas A. Jackson, Adnan Sharif

Summary: Frailty among haemodialysis patients is associated with hospitalization and mortality, but further discrimination of risk is needed due to the high prevalence of frailty. This study found that incorporating self-reported health with frailty measurement can help identify the most at-risk frail individuals.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Urology & Nephrology

Depression is associated with frailty and lower quality of life in haemodialysis recipients, but not with mortality or hospitalization

Benjamin M. Anderson, Muhammad Qasim, Gonzalo Correa, Felicity Evison, Suzy Gallier, Charles J. Ferro, Thomas A. Jackson, Adnan Sharif

Summary: Depression and frailty are common in haemodialysis recipients and are associated with negative outcomes. When taking frailty into account, depression is associated with lower hospitalization rates but poorer quality of life. Frailty is associated with higher admission rates, mortality, and poorer quality of life. The relationship between frailty and depression and their influence on outcomes is complex and requires further study.

CLINICAL KIDNEY JOURNAL (2023)

Review Urology & Nephrology

Impact of public restrictive measures on hypertension during the COVID-19 pandemic: existing evidence and long-term implications

Artemios G. Karagiannidis, Marieta P. Theodorakopoulou, Charles J. Ferro, Alberto Ortiz, Maria Jose Soler, Jean-Michel Halimi, Andrzej Januszewicz, Alexandre Persu, Reinhold Kreutz, Pantelis Sarafidis

Summary: Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2 and has become a global pandemic since December 2019. The public restrictive measures implemented in different countries have greatly affected people's daily activities. It is important to understand the impact of these measures on hypertension incidence and blood pressure control.

CLINICAL KIDNEY JOURNAL (2023)

Article Urology & Nephrology

Bone Mineral Density and Vascular Calcification in Children and Young Adults With CKD 4 to 5 or on Dialysis

Alexander D. Lalayiannis, Nicola J. Crabtree, Charles J. Ferro, David C. Wheeler, Neill D. Duncan, Colette Smith, Joyce Popoola, Askiti Varvara, Andromachi Mitsioni, Amrit Kaur, Manish D. Sinha, Lorenzo Biassoni, Simon P. McGuirk, Kristian H. Mortensen, David V. Milford, Jin Long, Mary D. Leonard, Mary Fewtrell, Rukshana Shroff

Summary: This multicenter longitudinal study found that while older adults with chronic kidney disease (CKD) may experience increases in bone mineral density (BMD), they can still develop vascular calcification. In contrast, the growing skeleton of children and young adults with CKD may offer protection against extraosseous calcification. These findings suggest that the growing skeleton may have a buffering capacity against non-skeletal calcification.

KIDNEY INTERNATIONAL REPORTS (2023)

Article Cardiac & Cardiovascular Systems

Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study

Patrick B. Mark, Juan J. Carrero, Kunihiro Matsushita, Yingying Sang, Shoshana H. Ballew, Morgan E. Grams, Josef Coresh, Aditya Surapaneni, Nigel J. Brunskill, John Chalmers, Lili Chan, Alex R. Chang, Rajkumar Chinnadurai, Gabriel Chodick, Massimo Cirillo, Dick de Zeeuw, Marie Evans, Amit X. Garg, Orlando M. Gutierrez, Hiddo J. L. Heerspink, Gunnar H. Heine, William G. Herrington, Junichi Ishigami, Florian Kronenberg, Jun Young Lee, Adeera Levin, Rupert W. Major, Angharad Marks, Girish N. Nadkarni, David M. J. Naimark, Christoph Nowak, Mahboob Rahman, Charumathi Sabanayagam, Mark Sarnak, Simon Sawhney, Markus P. Schneider, Varda Shalev, Jung-Im Shin, Moneeza K. Siddiqui, Nikita Stempniewicz, Keiichi Sumida, Jose M. Valdivielso, Jan van den Brand, Angela Yee-Moon Wang, David C. Wheeler, Lihua Zhang, Frank L. J. Visseren, Benedicte Stengel

Summary: This study investigated the association between cardiovascular disease (CVD) and future risk of kidney failure with replacement therapy (KFRT). It found that both prevalent and incident CVD were strongly associated with KFRT risk, with incident HF showing the strongest association.

EUROPEAN HEART JOURNAL (2023)

Review Endocrinology & Metabolism

Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies

Anna K. Forbes, Rebecca J. Suckling, William Hinton, Michael D. Feher, Debasish Banerjee, Nicholas I. Cole, Simon de Lusignan, Pauline A. Swift

Summary: This systematic review of observational studies indicates that SGLT2 inhibitors have significant kidney benefits for a diverse population of adults with type 2 diabetes. The meta-analysis shows that SGLT2 inhibitors are associated with a 46% lower risk of kidney failure events compared to other glucose-lowering drugs, regardless of baseline eGFR or albuminuria status.

DIABETES OBESITY & METABOLISM (2023)

Article Urology & Nephrology

Defining myocardial infarction in trials of people receiving hemodialysis: consensus report from the SONG-HD MI Expert Working group

Emma O'Lone, Fred S. Apple, James O. Burton, Fergus J. Caskey, Jonathan C. Craig, Christopher R. deFilippi, Derek Forfang, Karen A. Hicks, Vivekanand Jha, Kenneth W. Mahaffey, Patrick B. Mark, Patrick Rossignol, Nicole Scholes-Robertson, Allison Jaue, Andrea K. Viecelli, Angela Y. Wang, David C. Wheele, David White, Wolfgang C. Winkelmayer, Charles A. Herzog

Summary: Cardiovascular disease is the leading cause of death in hemodialysis patients. However, there is currently no standardized definition of myocardial infarction (MI) for this population. The international working group recommends specific approaches for interpreting ischemic symptoms and performing baseline electrocardiograms to improve the accuracy of MI diagnosis in hemodialysis patients. While baseline cardiac troponin values are not recommended, serial cardiac biomarkers should be obtained when ischemia is suspected.

KIDNEY INTERNATIONAL (2023)

Review Transplantation

SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA

Patrick B. Mark, Pantelis Sarafidis, Robert Ekart, Charles J. Ferro, Olga Balafa, Beatriz Fernandez-Fernandez, William G. Herrington, Patrick Rossignol, Lucia Del Vecchio, Jose M. Valdivielso, Francesca Mallamaci, Alberto Ortiz, Ionut Nistor, Mario Cozzolino

Summary: Chronic kidney disease (CKD) affects an estimated 850 million people worldwide and the leading causes are diabetes and hypertension. CKD can progress to end-stage kidney disease, requiring kidney replacement therapy. In addition, CKD is a risk factor for cardiovascular disease. Previously, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) were the mainstay of treatment, but they did not reduce cardiovascular events and mortality in CKD. However, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have shown cardiovascular and renal benefits in clinical trials, revolutionizing cardiorenal protection for patients with diabetes. Recent trials have demonstrated the benefits of SGLT2i in reducing heart failure and progression to kidney failure in patients with CKD and/or heart failure. Specialty societies' guidelines are adapting to support wider use of SGLT2i. The consensus paper from EURECA-m and ERBP summarizes the latest evidence and guidelines for using SGLT2i for cardiorenal protection in CKD patients.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Urology & Nephrology

A Randomized Trial of Intravenous Iron Supplementation and Exercise on Exercise Capacity in Iron-Deficient Nonanemic Patients With CKD

Sharlene A. Greenwood, Benjamin A. Oliveira, Elham Asgari, Salma Ayis, Luke A. Baker, Nicholas Beckley-Hoelscher, Aicha Goubar, Debasish Banerjee, Sunil Bhandari, Joseph Chilcot, James O. Burton, Philip A. Kalra, Courtney J. Lightfoot, Iain C. Macdougall, Kieran McCafferty, Thomas H. Mercer, Darlington O. Okonko, Chante Reid, Fiona Reid, Alice C. Smith, Pauline A. Swift, Anastasios Mangelis, Emma Watson, David C. Wheeler, Thomas J. Wilkinson, Kate Bramham

Summary: This trial evaluated the effects of iron supplementation on exercise capacity of nonanemic patients with CKD. The results showed that IV iron therapy did not improve exercise capacity at 4 weeks. A larger study is needed to confirm the benefits of IV iron in iron-deficient non-dialysis CKD patients.

KIDNEY INTERNATIONAL REPORTS (2023)

Article Urology & Nephrology

Cognitive Impairment, Frailty, and Adverse Outcomes Among Prevalent Hemodialysis Recipients: Results From a Large Prospective Cohort Study in the United Kingdom

Benjamin M. Anderson, Muhammad Qasim, Gonzalo Correa, Felicity Evison, Suzy Gallier, Charles J. Ferro, Thomas A. Jackson, Adnan Sharif

Summary: This study aimed to explore the relationship between frailty scores and cognition, and their associations with hospitalization and mortality. The results showed that increasing frailty by all definitions was associated with poorer cognition. However, cognitive impairment was not directly associated with mortality or hospitalization, but rather correlated with increasing frailty scores.

KIDNEY MEDICINE (2023)

Article Cardiac & Cardiovascular Systems

Cardiac Troponin, Kidney Function, Heart Failure and Mortality After Myocardial Infarction in Patients With and Without Kidney Impairment

Daniel Murphy, Sami Firoozi, Charles A. Herzog, Debasish Banerjee

Summary: In this study, the relationship between cardiac troponin levels, estimated glomerular filtration rate (eGFR), postinfarction heart failure (HF), and mortality in patients with kidney impairment was investigated. The results showed that peak cardiac troponin T level and eGFR were independent predictors of acute HF severity and death.

AMERICAN JOURNAL OF CARDIOLOGY (2023)

Review Urology & Nephrology

Diagnosis of cardiovascular disease in patients with chronic kidney disease

Carmine Zoccali, Patrick B. Mark, Pantelis Sarafidis, Rajiv Agarwal, Marcin Adamczak, Rodrigo Bueno de Oliveira, Ziad A. Massy, Peter Kotanko, Charles J. Ferro, Christoph Wanner, Michel Burnier, Raymond Vanholder, Francesca Mallamaci, Andrzej Wiecek

Summary: Patients with CKD are at high risk of CVD, so it's important to identify and monitor cardiovascular complications and hypertension. Biomarkers like troponins and ECG have limited use in diagnosing cardiac ischemia in these patients. However, techniques like stress echocardiography, myocardial perfusion scintigraphy, and stress testing can help detect coronary disease in patients with CKD.

NATURE REVIEWS NEPHROLOGY (2023)

Editorial Material Urology & Nephrology

GFR slope as a surrogate marker for future kidney failure

Jennifer S. Lees, Patrick B. Mark

Summary: Kidney failure is a serious consequence of chronic kidney disease, and a meta-analysis has confirmed the validity and reliability of glomerular filtration rate (GFR) slope as a surrogate marker for kidney failure, despite the varied treatments and disease groups.

NATURE REVIEWS NEPHROLOGY (2023)

Review Transplantation

COVID-19 and cardiovascular disease in patients with chronic kidney disease

Lucia Del Vecchio, Olga Balafa, Evangelia Dounousi, Robert Ekart, Beatriz Fernandez Fernandez, Patrick B. Mark, Pantelis Sarafidis, Jose M. Valdivielso, Charles J. Ferro, Francesca Mallamaci

Summary: Patients with chronic kidney disease (CKD) are at high risk for cardiovascular (CV) complications due to infection with SARS-CoV-2. These complications, including acute inflammatory manifestations, CV events, thrombotic episodes, and arrythmias, can occur during the acute phase of the infection and months after recovery, potentially due to direct viral damage to the myocardium, endothelial damage, and hypercoagulability.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

暂无数据